Michèle Myriam Rauber

Michèle Myriam Rauber

Auto-generated profile, based on publicly available information

Michèle Myriam Rauber

Clinical & Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
FJFrederic Jabs
Frederic Jabs
MPMelanie Plum
Melanie Plum
NLNick Stub Laursen
Nick Stub Laursen
RJRasmus K. Jensen
Rasmus K. Jensen
BMBrian Mølgaard
Brian Mølgaard
ESEdzard Spillner
Edzard Spillner
Anti-IgE therapeutics interfere with the ability of IgE to bind to its receptors on effector cells. Here we report the crystal structure of an anti-IgE single-domain antibody in complex with an IgE Fc fragment, revealing how the antibody inhibits interactions between IgE and the two receptors FcεRI and CD23. The epitope overlaps only slightly with the FcεRI-binding site but significantly with the CD23-binding site. Solution scattering studies of the IgE Fc reveal that antibody binding induces a half-bent conformation in between the well-known bent and extended IgE Fc conformations. The antibody acts as functional homolog of CD23 and induces a closed conformation of IgE Fc incompatible with FcεRI binding. Notably the antibody displaces IgE from both CD23 and FcεRI, and abrogates allergen-mediated basophil activation and facilitated allergen binding. The inhibitory mechanism might facilitate strategies for the future development of anti-IgE therapeutics for treatment of allergic diseases.

12 July 2017 in Allergy
Verified
Journal Article
Closed access
PDF file
MRM. M. Rauber
M. M. Rauber
JPJ. Pickert
J. Pickert
LHL. Holiangu
L. Holiangu
CMC. Möbs
C. Möbs
WPW. Pfützner
W. Pfützner

13 March 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
MRMichèle Myriam Rauber
Michèle Myriam Rauber
HWHoi Ka Wu
Hoi Ka Wu
BABritta Adams
Britta Adams
JPJulia Pickert
Julia Pickert
BBBarbara Bohle
Barbara Bohle
CMChristian Möbs
Christian Möbs

22 July 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
MRMichèle Myriam Rauber
Michèle Myriam Rauber
CMChristian Möbs
Christian Möbs
RCRaffaela A. Campana
Raffaela A. Campana
RHRainer Henning
Rainer Henning
MSManuel Schulze‐Dasbeck
Manuel Schulze‐Dasbeck
WPWolfgang Pfützner
Wolfgang Pfützner

16 June 2020 in Current Allergy and Asthma Reports
Verified
Journal Article
Open access
PDF file
TJThilo Jakob
Thilo Jakob
MRMichèle Myriam Rauber
Michèle Myriam Rauber
APAmilcar Pérez-Riverol
Amilcar Pérez-Riverol
ESEdzard Spillner
Edzard Spillner
Simon BlankSimon Blank
Simon Blank
Purpose of Review: In Hymenoptera venom allergy, the research focus has moved from whole venoms to individual allergenic molecules. Api m 10 (icarapin) has been described as a major allergen of honeybee venom (HBV) with potentially high relevance for diagnostics and therapy of venom allergy. Here, we review recent studies on Api m 10 characteristics as well as its role in component-resolved diagnostics and potential implications for venom-specific immunotherapy (VIT). Recent Findings: Api m 10 is a major allergen of low abundance in HBV. It is an obviously unstable protein of unknown function that exhibits homologs in other insect species. Despite its low abundance in HBV, 35 to 72% of HBV-allergic patients show relevant sensitization to this allergen. Api m 10 is a marker allergen for HBV sensitization, which in many cases can help to identify primary sensitization to HBV and, hence, to discriminate between genuine sensitization and cross-reactivity. Moreover, Api m 10 might support personalized risk stratification in VIT, as dominant sensitization to Api m 10 has been identified as risk factor for treatment failure. This might be of particular importance since Api m 10 is strongly underrepresented in some therapeutic preparations commonly used for VIT. Summary: Although the role of Api m 10 in HBV allergy and tolerance induction during VIT is not fully understood, it certainly is a useful tool to unravel primary sensitization and individual sensitization profiles in component-resolved diagnostics (CRD). Moreover, a potential of Api m 10 to contribute to personalized treatment strategies in HBV allergy is emerging.

18 January 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
MRM.M. Rauber
M.M. Rauber
JPJ. Pickert
J. Pickert
LHL. Holiangu
L. Holiangu
CMC. Möbs
C. Möbs
WPW. Pfützner
W. Pfützner
Background: The anti‐IgE antibody omalizumab has been approved for the treatment of chronic spontaneous urticaria (CSU) in patients insufficiently responding to antihistamines. However, its mode of action in CSU is not clearly understood.Objectives: The aim of this study was to get a better insight in the immune mechanisms involved in clinical improvement of CSU patients treated with omalizumab.Methods: Chronic spontaneous urticaria patients (n = 15) were followed for 5 months after initiation of omalizumab treatment. Clinical symptoms were assessed by UCT and CU‐Q2oL. Cell‐bound IgE was quantified on both FcεRI‐ and FcεRII‐expressing cell populations in peripheral blood. In addition, IgE and IgG as well as their receptors were measured on basophils, and basophil activation was assessed with different concentrations of anti‐FcεRI and fMLP. Furthermore, the frequencies of different T‐cell subsets secreting IL‐5, IL‐10, IL‐31 or IFN‐γ were analysed by ELISpot assay.Results: Seven patients showed a full, five a partial and three no clinical response to omalizumab. Cell‐bound IgE was reduced on FcεRI‐bearing cells, but not on FcεRII‐expressing cells. Likewise, the expression of FcεRI declined. Basophil activation increased upon FcεRI‐stimulation while their sensitivity was not affected. Both basophil and T‐cell frequencies remained unchanged. However, when comparing the individual response to omalizumab treatment with distinct T‐cell subsets, a significant correlation was found between improved UCT and decreased frequencies of IL‐10‐, IL‐31‐ and IFN‐γ‐secreting T cells.Conclusions: We here show that besides addressing IgE‐dependent immune mechanisms, omalizumab treatment of CSU patients has effects on distinct T‐cell subsets, which correlate with clinical improvement.